Keros Therapeutics (KROS)

What Moves the Stock

1. 01Phase 2/3 clinical trial data readouts for cibotercept in pulmonary arterial hypertension (primary endpoint: 6-minute walk distance improvement)
2. 02Myelofibrosis trial enrollment progress and interim efficacy signals for cibotercept (spleen volume reduction, symptom scores)
3. 03Elritercept bone mineral density and anemia data in Phase 2 studies for myelodysplastic syndromes
4. 04FDA regulatory interactions, breakthrough therapy designations, or accelerated approval pathway discussions
5. 05Strategic partnership announcements or licensing deals that provide non-dilutive funding and validation
6. 06Equity financing announcements and cash runway extensions (dilution concerns vs. trial funding security)
7. 07No material commercial revenue currently - pre-revenue clinical stage
8. 08Potential future milestone payments from strategic partnerships (timing uncertain)

KROS Chart

My Notes

• growth - Attracts speculative biotech investors focused on binary clinical catalysts and multi-bagger potential from successful drug…
• Rising interest rates negatively impact Keros through two channels: (1) Higher discount rates compress NPV of distant future cash flows…
• Watch on earnings: Clinical trial milestone announcements and data presentation schedules (ASH, ERS, AHA conferences), Patient enrollment completion rates in ongoing Phase 2/3 studies, Cash and marketable securities balance relative to quarterly burn rate.